The EU-funded project CARAT offers fellowships for a training course on CAR T cell manufacturing
CARAT is taking on the mission to deliver new methods to enable the wide use of novel personalised cancer treatment options. In 2017, CARAT invites five scientists to participate in a unique training event at Miltenyi Biotec which has the aim of transferring knowledge on GMP compliant CAR T cell manufacturing to scientists in the field. Scientists with a profound background in cellular and gene therapy who intend to initiate clinical applications in the near future can apply for the fellowship.
11 December 2017 - 15 December 2017
The EU-funded project Chimeric Antigen Receptors (CARs) for Advanced Therapies (CARAT) aims to develop a new, comprehensive platform for innovative cell manufacturing technologies as part of the European Horizon 2020 research and innovation programme. In order to accomplish the goal of providing a safe, automated, and cost-efficient manufacture of effective CAR T cells for personalised cancer therapies, CARAT, consisting of eight partners from four different European countries, was initiated. Within the framework of CARAT, a training course on GMP compliant CAR T cell manufacturing will be organised. This training event will take place in December 2017 at Miltenyi Biotec’s headquarters in Bergisch Gladbach, Germany.
The CARAT training fellowship
The fellowship is tailored towards experienced scientists in the cellular and gene therapy field, who expect to initiate clinical applications in the near future. The 5-day training course will transmit know-how on GMP compliant CAR T cell manufacturing, with a focus on practical, regulatory and scientific matters, to five selected trainees. Objectives of the training event include an introduction to cell separation technology, a deep overview of the T cell transduction (TCT) process on the automated CliniMACS Prodigy® cell processing platform, and an active exchange about regulatory requirements including clinical trial design and approval processes. After the course, each CARAT trainee will be prepared to independently perform the automated manufacture of cellular products as well as manage logistical aspects such as GMP compliance and adherence to monitoring guidelines.
Applicants from EU Member States and Associated Countries are encouraged to participate and submit their applications by May 31, 2017. Submitted applications will be carefully peer-reviewed by the CARAT Steering Committee, considering the scientific background of applicants as well as gender balance and regional aspects. All applicants will be informed about the decision no later than three months after the submission deadline.
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company’s innovative tools support research at every level, from basic research over translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyse, and utilise the cell. Miltenyi Biotec’s technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. With more than 25 years of expertise they cover a variety of research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In their commitment to the scientific community, Miltenyi Biotec also offers comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 1,700 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
Fellowship, CAR T cells, cancer therapy, Chimeric Antigen Receptors, cell manufacturing, GMP compliant, training